170 related articles for article (PubMed ID: 35939081)
1. Validating the screening criteria for bone metastases in treatment-naïve unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.
Rud E; Noor D; Galtung KF; Ottosson F; Jacewicz M; Baco E; Lauritzen PM
Eur Radiol; 2022 Dec; 32(12):8266-8275. PubMed ID: 35939081
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
4. The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer.
Ottosson F; Baco E; Lauritzen PM; Rud E
Eur Radiol; 2021 May; 31(5):2747-2753. PubMed ID: 33141299
[TBL] [Abstract][Full Text] [Related]
5. Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT.
Borley N; Fabrin K; Sriprasad S; Mondaini N; Thompson P; Muir G; Poulsen J
Scand J Urol Nephrol; 2003; 37(5):382-6. PubMed ID: 14594685
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study assessing the accuracy of [18F]-fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection.
Puterman C; Bjöersdorff M; Amidi J; Anand A; Soller W; Jiborn T; Kjölhede H; Trägårdh E; Bjartell A
Scand J Urol; 2021 Aug; 55(4):293-297. PubMed ID: 33939583
[TBL] [Abstract][Full Text] [Related]
7. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
[TBL] [Abstract][Full Text] [Related]
8. The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
Meijer D; de Barros HA; van Leeuwen PJ; Bodar YJL; van der Poel HG; Donswijk ML; Hendrikse NH; van Moorselaar RJA; Nieuwenhuijzen JA; Oprea-Lager DE; Vis AN
J Urol; 2021 Jun; 205(6):1655-1662. PubMed ID: 33530746
[TBL] [Abstract][Full Text] [Related]
9. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study.
Heesakkers RA; Hövels AM; Jager GJ; van den Bosch HC; Witjes JA; Raat HP; Severens JL; Adang EM; van der Kaa CH; Fütterer JJ; Barentsz J
Lancet Oncol; 2008 Sep; 9(9):850-6. PubMed ID: 18708295
[TBL] [Abstract][Full Text] [Related]
10. Obesity strongly predicts clinically undetected multiple lymph node metastases in intermediate- and high-risk prostate cancer patients who underwent robot assisted radical prostatectomy and extended lymph node dissection.
Tafuri A; Amigoni N; Rizzetto R; Sebben M; Shakir A; Gozzo A; Odorizzi K; De Michele M; Gallina S; Bianchi A; Ornaghi P; Brunelli M; De Marco V; Verratti V; Migliorini F; Cerruto MA; Artibani W; Antonelli A; Porcaro AB
Int Urol Nephrol; 2020 Nov; 52(11):2097-2105. PubMed ID: 32607958
[TBL] [Abstract][Full Text] [Related]
11. 11C-Choline PET/CT in the primary diagnosis of prostate cancer: impact on treatment planning.
Garcia JR; Jorcano S; Soler M; Linero D; Moragas M; Riera E; Miralbell R; Lomeña F
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):342-50. PubMed ID: 24844254
[TBL] [Abstract][Full Text] [Related]
12. The role of MRI in the management of a prostate cancer patient with bone and lymph nodes metastases. A case report.
Belmonte M; Saia G; Zugni F; Alessi S; Colombo A; Summers PE; Luzzago S; Marvaso G; Musi G; De Cobelli O; Jereczek-Fossa BA; Petralia G
Acta Biomed; 2021 Sep; 92(4):e2021214. PubMed ID: 34487080
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Lymph Node Invasion in Patients with Clinically Localized Prostate Cancer Who Undergo Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: The Role of Obesity.
Tafuri A; Rizzetto R; Amigoni N; Sebben M; Shakir A; Gozzo A; Odorizzi K; Gallina S; Bianchi A; Ornaghi P; Brunelli M; Migliorini F; Cerruto MA; Artibani W; Siracusano S; Antonelli A; Porcaro AB
Urol Int; 2021; 105(5-6):362-369. PubMed ID: 33059351
[TBL] [Abstract][Full Text] [Related]
14. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
[TBL] [Abstract][Full Text] [Related]
15. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer.
van Kalmthout LWM; van Melick HHE; Lavalaye J; Meijer RP; Kooistra A; de Klerk JMH; Braat AJAT; Kaldeway HP; de Bruin PC; de Keizer B; Lam MGEH
J Urol; 2020 Mar; 203(3):537-545. PubMed ID: 31487220
[TBL] [Abstract][Full Text] [Related]
16. Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.
Larbi A; Dallaudière B; Pasoglou V; Padhani A; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
Prostate; 2016 Aug; 76(11):1024-33. PubMed ID: 27197649
[TBL] [Abstract][Full Text] [Related]
17. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
18.
Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
[TBL] [Abstract][Full Text] [Related]
19. Results of laparoscopic pelvic lymphadenectomy in patients at high risk for nodal metastases from prostate cancer.
Kava BR; Dalbagni G; Conlon KC; Russo P
Ann Surg Oncol; 1998 Mar; 5(2):173-80. PubMed ID: 9527271
[TBL] [Abstract][Full Text] [Related]
20. External evaluation of the Briganti nomogram to predict lymph node metastases in intermediate-risk prostate cancer patients.
Peilleron N; Seigneurin A; Herault C; Verry C; Bolla M; Rambeaud JJ; Descotes JL; Long JA; Fiard G
World J Urol; 2021 May; 39(5):1489-1497. PubMed ID: 32583038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
